WKHS Locations

Clinical Trials

Study Title

Sativex 962

Purpose

A double blind, randomized, placebo-controlled, parallel group study of Sativex oromucosal spray (Sativex®; Nabiximols) as adjunctivetherapy in relieving uncontrolled persistent chronic pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy; Three hundred and eighty patients (190 per treatment arm (Sativex or placebo)

Eligibility

Contact Principal Investigator for Information

Study Process

Contact Principal Investigator for Information

Trial Details

Principal Investigator:

Matthew Mosura, M.D.

IRB:

Quorum

IRB Number:

Trial Type:

Drug

Sponsor:

Otsuka / GW Pharma

Contact Information:

River Cities Interventional Pain Specialists
(318) 212-7960